text:
Anxiolytic

An anxiolytic (also antipanic or anti-anxiety agent) is a medication or other intervention that reduces anxiety. This effect is in contrast to anxiogenic agents which increase anxiety. Anxiolytic medications are used for the treatment of anxiety disorders and their related psychological and physical symptoms.

Nature of anxiety
Anxiety is a naturally-occurring emotion and response. When anxiety levels exceed the tolerability of a person, anxiety disorders may occur. People with anxiety disorders can exhibit fear responses, such as defensive behaviors, high levels of alertness, and negative emotions. Those with anxiety disorders may have concurrent psychological disorders, such as depression. Anxiety disorders are classified using six possible clinical assessments: Different types of anxiety disorders will share some general symptoms while having their own distinctive symptoms. This explains why people with different types of anxiety disorders will respond differently to different classes of anti-anxiety medications.

Etiology
The etiology of anxiety disorder remains unknown. There are several contributing factors that are still yet to be proved to cause anxiety disorders. These factors include childhood anxiety, drug induction by central stimulant drugs, metabolic diseases or having depressive disorder.

Medications
Anti-anxiety medication is any drug that can be taken or prescribed for the treatment of anxiety disorders, which may be mediated by neurotransmitters like norepinephrine, serotonin, dopamine, and gamma-aminobutyric acid (GABA) in the central nervous system. Anti-anxiety medication can be classified into six types according to their different mechanisms: antidepressants, benzodiazepines, azapirones, antiepileptics, antipsychotics, and beta blockers.

Antidepressants include selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCA), monoamine oxidase inhibitor (MAOI). SSRIs are used in all types of anxiety disorders while SNRIs are used for generalized anxiety disorder (GAD). Both of them are considered as first-line anti-anxiety medications. TCAs are second-line treatment as they cause more significant adverse effects when compared to the first-line treatment. Benzodiazepines are effective in emergent and short-term treatment of anxiety disorders due to their fast onset but carry the risk of dependence. Buspirone is indicated for GAD, which has much slower onset but with the advantage of less sedating and withdrawal effects.

History
The first monoamine oxidase inhibitor (MAOI), iproniazid, was discovered accidentally when developing the new antitubercular drug isoniazid. The drug was found to induce euphoria and improve the patient's appetite and sleep quality.

The first tricyclic antidepressant, imipramine, was originally developed and studied to be an antihistamine alongside other first-generation antihistamines of the time, such as promethazine. TCAs can increase the level of norepinephrine and serotonin by inhibiting their reuptake transport proteins. The majority of TCAs exert greater effect on norepinephrine, which leads to side effects like drowsiness and memory loss.

In order to be more effective on serotonin agonism and avoid anticholinergic and antihistaminergic side effects, selective serotonin reuptake inhibitors (SSRI) were researched and introduced to treat anxiety disorders. The first SSRI, fluoxetine (Prozac), was discovered in 1974 and approved by FDA in 1987. After that, other SSRIs like sertraline (Zoloft), paroxetine (Paxil), and escitalopram (Lexapro) have entered the market.

The first serotonin norepinephrine reuptake inhibitor (SNRI), venlafaxine (Effexor), entered the market in 1993. SNRIs can target serotonin and norepinephrine transporters while avoiding imposing significant effects on other adrenergic (α1, α2, and β), histamine (H1), muscarinic, dopamine, or postsynaptic serotonin receptors.

Classifications
There are six groups of anti-anxiety medications available that have been proven to be clinically significant in treatment of anxiety disorders. The groups of medications are as follows.

Antidepressants
Medications that are indicated for both anxiety disorders and depression. Selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs) are new generations of antidepressants. They have a much lower adverse effect profile than older antidepressants like monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressant (TCAs). Therefore, SSRIs and SNRIs are now the first-line agent in treating long term anxiety disorders, given their applications and significance in all six types of disorders.

Benzodiazepines
Benzodiazepines are used for acute anxiety and could be added along with current use of SSRIs to stabilize a treatment. Long-term use in treatment plans is not recommended. Different kinds of benzodiazepine will vary in its pharmacological profile, including its strength of effect and time taken for metabolism. The choice of the benzodiazepine will depend on the corresponding profiles.

Benzodiazepines are used for emergent or short-term management. They are not recommended as the first-line anti-anxiety drugs, but they can be used in combination with SSRIs/SNRIs during the initial treatment stage. Indications include panic disorder, sleep disorders, seizures, acute behavioral disturbance, muscle spasm and premedication and sedation for procedures.

Azapirones
Buspirone can be useful in GAD but not particularly effective in treating phobias, panic disorder or social anxiety disorders. It is a safer option for long-term use as it does not cause dependence like benzodiazepines.

Antiepileptics
Antiepileptics are rarely prescribed as an off-label treatment for anxiety disorders and post-traumatic stress disorders. There have been some suggestions that they may help with anxiety symptoms but there is generally a lack of research on its use.

One antiepileptic, pregabalin, has been found to be better at treating GAD than a placebo, and comparable effects to benzodiazepines. It has also been shown be potentially efficient in treating social anxiety disorder. Gabapentin has been prescribed off-label for anxiety despite a lack of research evidence supporting such use, although some studies have indicated that it may relieve anxiety symptoms. The potential anxiolytic effect of tiagabine has been observed in some pre-clinical trials, but its effectiveness has not yet been proved. Similarly, there is a lack of research on valproate for the treatment of anxiety disorders.

Antipsychotics
Olanzapine and risperidone are atypical antipsychotics which are also effective in GAD and PTSD treatment. However, there is a higher chance of experiencing adverse effects than the other anti-anxiety medications.

Beta-adrenoceptor antagonists
Propranolol is originally used for high blood pressure and heart diseases. It can also be used to treat anxiety with symptoms like tremor or increased heart rate. They work on the nervous system and alleviate the symptoms as a relief. Propranolol is also commonly used for public speaking when one is nervous.

SSRIs and SNRIs
Both selective serotonin reuptake inhibitors (SSRI) and serotonin and norepinephrine reuptake inhibitors (SNRI) are reuptake inhibitors of a class of nerve signal transduction chemical called neurotransmitters. Serotonin and norepinephrine are neurotransmitters that are related to nervous control in mood regulation. The level of neurotransmitters are regulated by the nerve through reuptake to avoid accumulation of the neurotransmitter at the endings of nerve fiber. By reuptaking the produced neurotransmitter, the level will go back down and be ready to go back up upon excitation from a new nerve signal. However the level of patients with anxiety disorders are usually low or their nerve fibers are insensitive to the neurotransmitters. SSRIs and SNRIs will then block the channel of reuptake and increase the level of the neurotransmitter. The nerve fibers will originally inhibit further production of neurotransmitters upon the increase. However the prolonged increase will eventually desensitize the nerve about the change in level. Therefore, the action of both SSRIs and SNRIs will take 4–6 weeks to exert their full effect.

Benzodiazepine
Benzodiazepines bind selectively to the GABA receptor, which is the receptor protein found in the nervous system and is in control of the nervous response. Benzodiazepine will increase the entry of chloride ions into the cells by improving the binding between GABA and GABA receptors and then the better opening of the channel for chloride ion passage. The high level of chloride ion inside the nerve cells makes the nerve more difficult to depolarize and inhibit further nerve signal transduction. The excitability of the nerves then reduces and the nervous system slows down. Therefore, the drug can alleviate symptoms of anxiety disorder and make the person less nervous.

Selective serotonin reuptake inhibitors
Selective serotonin reuptake inhibitors (SSRIs) are a class of medications used in the treatment of depression, anxiety disorders, OCD and some personality disorders. SSRIs are the first-line anti-anxiety medications. Serotonin is one of the crucial neurotransmitters in mood enhancement, and increasing serotonin level produces an anti-anxiety effect. SSRIs increase the serotonin level in the brain by inhibiting serotonin uptake pumps on serotonergic systems, without interactions with other receptors and ion channels. SSRIs are beneficial in both acute response and long-term maintenance treatment for both depression and anxiety disorder.

SSRIs can increase anxiety initially due to negative feedback through the serotonergic autoreceptors; for this reason a concurrent benzodiazepine can be used until the anxiolytic effect of the SSRI occurs.

The SSRIs paroxetine and escitalopram are USFDA approved to treat generalized anxiety disorder.

Adverse effect
The common early side effects of SSRIs include nausea and loose stool, which can be solved by discontinuing the treatment. Headache, dizziness, insomnia are the common early side effects as well.

Sexual dysfunction, anorgasmia, erectile dysfunction, and reduced libido are common adverse side effects of SSRIs. Sometimes they may persist after the cessation of treatment.

Withdrawal symptoms like dizziness, headache and flu-like symptoms (fatigue/myalgia/loose stool) may occur if SSRI is stopped suddenly. The brain is incapable of upregulating the receptors to sufficient levels especially after discontinuation of the drugs with short half life like paroxetine. Both fluoxetine and its active metabolite have a long half life therefore it causes the least withdrawal symptoms.

Serotonin–norepinephrine reuptake inhibitors
Serotonin–norepinephrine reuptake inhibitor (SNRIs) include venlafaxine and duloxetine drugs. Venlafaxine, in extended release form, and duloxetine, are indicated for the treatment of GAD. SNRIs are as effective as SSRIs in the treatment of anxiety disorders.

Tricyclic antidepressants
Tricyclic antidepressants (TCAs) have anxiolytic effects; however, side effects are often more troubling or severe and overdose is dangerous. They are considered effective, but have generally been replaced by antidepressants that cause different adverse effects. Examples include imipramine, doxepin, amitriptyline, nortriptyline and desipramine.

Contraindication
TCAs may cause drug poisoning in patients with hypotension, cardiovascular diseases and arrhythmias.

Tetracyclic antidepressants
Mirtazapine has demonstrated anxiolytic effect comparable to SSRIs while rarely causing or exacerbating anxiety. Mirtazapine's anxiety reduction tends to occur significantly faster than SSRIs.

Monoamine oxidase inhibitors
Monoamine oxidase inhibitors (MAOIs) are first-generation antidepressants effective for anxiety treatment but their dietary restrictions, adverse effect profile and availability of newer medications have limited their use. MAOIs include phenelzine, isocarboxazid and tranylcypromine. Pirlindole is a reversible MAOI that lacks dietary restriction.

Barbiturates
Barbiturates are powerful anxiolytics but the risk of abuse and addiction is high. Many experts consider these drugs obsolete for treating anxiety but valuable for the short-term treatment of severe insomnia, though only after benzodiazepines or non-benzodiazepines have failed.

Benzodiazepines
Benzodiazepines are prescribed to quell panic attacks. Benzodiazepines are also prescribed in tandem with an antidepressant for the latent period of efficacy associated with many ADs for anxiety disorder. There is risk of benzodiazepine withdrawal and rebound syndrome if BZDs are rapidly discontinued. Tolerance and dependence may occur. The risk of abuse in this class of medication is smaller than in that of barbiturates. Cognitive and behavioral adverse effects are possible.

Benzodiazepines include: alprazolam (Xanax), bromazepam, chlordiazepoxide (Librium), clonazepam (Klonopin), diazepam (Valium), lorazepam (Ativan), oxazepam, temazepam, and Triazolam.

Adverse effect
Benzodiazepines lead to central nervous system depression, resulting in common adverse effects like drowsiness, oversedation, light-headedness. Memory impairment can be a common adverse effect especially in elderly, hypersalivation, ataxia, slurred speech, psychomotor effects.

Sympatholytics
Sympatholytics are a group of anti-hypertensives which inhibit activity of the sympathetic nervous system. Beta blockers reduce anxiety by decreasing heart rate and preventing shaking. Beta blockers include propranolol, oxprenolol, and metoprolol. The alpha-1 antagonist prazosin could be effective for PTSD. The alpha-2 agonists clonidine and guanfacine have demonstrated both anxiolytic and anxiogenic effects.

Buspirone
Buspirone (Buspar) is a 5-HT1A receptor agonist used to treated generalized anxiety disorder. If an individual has only recently stopped taking benzodiazepines, buspirone will be less effective.

Pregabalin
Pregabalin (Lyrica) produces anxiolytic effect after one week of use comparable to lorazepam, alprazolam, and venlafaxine with more consistent psychic and somatic anxiety reduction. Unlike BZDs, it does not disrupt sleep architecture nor does it cause cognitive or psychomotor impairment.

Hydroxyzine
Hydroxyzine (Atarax) is an antihistamine originally approved for clinical use by the FDA in 1956. Hydroxyzine has a calming effect which helps ameliorate anxiety. Hydroxyzine efficacy is comparable to benzodiazepines in the treatment of generalized anxiety disorder.

Phenibut
Phenibut (Anvifen, Fenibut, Noofen) is an anxiolytic used in Russia. Phenibut is a GABAB receptor agonist, as well as an antagonist at α2δ subunit-containing voltage-dependent calcium channels (VDCCs), similarly to gabapentinoids like gabapentin and pregabalin. The medication is not approved by the FDA for use in the United States, but is sold online as a supplement.

Temgicoluril
Temgicoluril (Mebicar) is an anxiolytic produced in Latvia and used in Eastern Europe. Temgicoluril has an effect on the structure of limbic-reticular activity, particularly on the hypothalamus, as well as on all four basic neuromediator systems – γ aminobutyric acid (GABA), choline, serotonin and adrenergic activity. Temgicoluril decreases noradrenaline, increases serotonin, and exerts no effect on dopamine.

Fabomotizole
Fabomotizole (Afobazole) is an anxiolytic drug launched in Russia in the early 2000s. Its mechanism of action is poorly-defined, with GABAergic, NGF and BDNF release promoting, MT1 receptor agonism, MT3 receptor antagonism, and sigma receptor agonism thought to have some involvement.

Bromantane
Bromantane is a stimulant drug with anxiolytic properties developed in Russia during the late 1980s. Bromantane acts mainly by facilitating the biosynthesis of dopamine, through indirect genomic upregulation of relevant enzymes (tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AAAD)).

Emoxypine
Emoxypine is an antioxidant that is also a purported anxiolytic. Its chemical structure resembles that of pyridoxine, a form of vitamin B6.

Menthyl isovalerate
Menthyl isovalerate is a flavoring food additive marketed as a sedative and anxiolytic drug in Russia under the name Validol.

Racetams
Some racetam based drugs such as aniracetam can have an antianxiety effect.

Alpidem
Alpidem is a nonbenzodiazepine anxiolytic with similar anxiolytic effectiveness as benzodiazepines but reduced sedation and cognitive, memory, and motor impairment. It was marketed briefly in France but was withdrawn from the market due to liver toxicity.

Etifoxine
Etifoxine has similar anxiolytic effects as benzodiazepine drugs, but does not produce the same levels of sedation and ataxia. Further, etifoxine does not affect memory and vigilance, and does not induce rebound anxiety, drug dependence, or withdrawal symptoms.

Alcohol
Alcohol is sometimes used as an anxiolytic by self-medication. fMRI can measure the anxiolytic effects of alcohol in the human brain.

Alternatives to medication
Cognitive behavioral therapy (CBT) is an effective treatment for panic disorder, social anxiety disorder, generalized anxiety disorder, and obsessive–compulsive disorder, while exposure therapy is the recommended treatment for anxiety related phobias. Healthcare providers can guide those with anxiety disorder by referring them to self-help resources. Sometimes medication is combined with psychotherapy but research has not found a benefit of combined pharmacotherapy and psychotherapy versus monotherapy.

If CBT is found ineffective, both the Canadian and American medical associations then suggest the use of medication.

title: Anxiolytic


text:
Antipsychotic

Antipsychotics, previously known as neuroleptics and major tranquilizers, are a class of psychotropic medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia but also in a range of other psychotic disorders. They are also the mainstay, together with mood stabilizers, in the treatment of bipolar disorder. Moreover, they are also used as adjuncts in the treatment of treatment-resistant major depressive disorder.

Use of any antipsychotic is associated with reductions in brain tissue volumes, including white matter reduction,  an effect which is dose-dependent and time-dependent. A recent controlled trial suggests that second generation antipsychotics combined with intensive psychosocial therapy may potentially prevent pallidal brain volume loss in first episode psychosis.

The use of antipsychotics may result in many unwanted side effects such as involuntary movement disorders, gynecomastia, impotence, weight gain and metabolic syndrome. Long-term use can produce adverse effects such as tardive dyskinesia, tardive dystonia, and tardive akathisia.

First-generation antipsychotics (e.g., chlorpromazine), known as typical antipsychotics, were first introduced in the 1950s, and others were developed until the early 1970s. Second-generation antipsychotics, known as atypical antipsychotics, arrived with the introduction of clozapine in the early 1970s followed by others (e.g., risperidone). Both generations of medication block receptors in the brain for dopamine, but atypicals block serotonin receptors as well. Third-generation antipsychotics were introduced in the 2000s and offer partial agonism, rather than blockade, of dopamine receptors. Neuroleptic, originating from νεῦρον (neuron) and λαμβάνω (take hold of)—thus meaning "which takes the nerve"—refers to both common neurological effects and side effects.

Medical uses
Antipsychotics are most frequently used for the following conditions:
 * Schizophrenia
 * Schizoaffective disorder most commonly in conjunction with either an antidepressant (in the case of the depressive subtype) or a mood stabilizer (in the case of the bipolar subtype). Antipsychotics possess mood stabilizing properties and thus they may be used as standalone medication to treat mood dysregulation.
 * Bipolar disorder (acute mania and mixed episodes) may be treated with either typical or atypical antipsychotics, although atypical antipsychotics are usually preferred because they tend to have more favourable adverse effect profiles and, according to a recent meta-analysis, they tend to have a lower liability for causing conversion from mania to depression.
 * Psychotic depression. In this indication it is a common practice for the psychiatrist to prescribe a combination of an atypical antipsychotic and an antidepressant as this practice is best supported by the evidence.
 * Treatment resistant depression as an adjunct to standard antidepressant therapy.

Given the limited options available to treat the behavioral problems associated with dementia, other pharmacological and non-pharmacological interventions are usually attempted before using antipsychotics. A risk-to-benefit analysis is performed to weigh the risk of the adverse effects of antipsychotics versus: the potential benefit, the adverse effects of alternative interventions, and the risk of failing to intervene when a patient's behavior becomes unsafe. The same can be said for insomnia, in which they are not recommended as first-line therapy. There are evidence-based indications for using antipsychotics in children (e.g., tic disorder, bipolar disorder, psychosis), but the use of antipsychotics outside of those contexts (e.g., to treat behavioral problems) warrants significant caution.

Antipsychotics are used to treat tics associated with Tourette syndrome. Aripiprazole, an atypical antipsychotic, is used as add-on medication to ameliorate sexual dysfunction as a symptom of selective serotonin reuptake inhibitor antidepressants in women. Quetiapine is used to treat generalized anxiety disorder.

Schizophrenia
Antipsychotic drug treatment is a key component of schizophrenia treatment recommendations by the National Institute of Health and Care Excellence (NICE), the American Psychiatric Association, and the British Society for Psychopharmacology. The main aim of treatment with antipsychotics is to reduce the positive symptoms of psychosis, that include delusions and hallucinations. There is mixed evidence to support a significant impact of antipsychotic use on primary negative symptoms (such as apathy, lack of emotional affect, and lack of interest in social interactions) or on cognitive symptoms (memory impairments, reduced ability to plan and execute tasks). In general, the efficacy of antipsychotic treatment in reducing positive symptoms appears to increase with the severity of baseline symptoms. All antipsychotic medications work relatively the same way: by antagonizing D2 dopamine receptors. However, there are some differences when it comes to typical and atypical antipsychotics. For example, atypical antipsychotic medications have been seen to lower the neurocognitive impairment associated with schizophrenia more than conventional antipsychotics, although the reasoning and mechanics of this are still unclear to researchers.

Applications of antipsychotic drugs in the treatment of schizophrenia include prophylaxis for those showing symptoms that suggest that they are at high risk of developing psychosis; treatment of first-episode psychosis; maintenance therapy (a form of prophylaxis, maintenance therapy aims to maintain therapeutic benefit and prevent symptom relapse); and treatment of recurrent episodes of acute psychosis.

Prevention of psychosis and symptom improvement
Test batteries such as the PACE (Personal Assessment and Crisis Evaluation Clinic) and COPS (Criteria of Prodromal Syndromes), which measure low-level psychotic symptoms and cognitive disturbances, are used to evaluate people with early, low-level symptoms of psychosis. Test results are combined with family history information to identify patients in the "high-risk" group; they are considered to have a 20–40% risk of progression to frank psychosis within two years. These patients are often treated with low doses of antipsychotic drugs with the goal of reducing their symptoms and preventing progression to frank psychosis. While generally useful for reducing symptoms, clinical trials to date show little evidence that early use of antipsychotics improves long-term outcomes in those with prodromal symptoms, either alone or in combination with cognitive-behavioral therapy.

First-episode psychosis
First-episode psychosis (FEP) is the first time that psychotic symptoms are presented. NICE recommends that all people presenting with first-episode psychosis be treated with both an antipsychotic drug and cognitive behavioral therapy (CBT). NICE further recommends that those expressing a preference for CBT alone be informed that combination treatment is more effective. A diagnosis of schizophrenia is not made at this time as it takes longer to be determined by both DSM-5 and ICD-11, and only around 60% of those presenting with a first episode of psychosis will later be diagnosed with schizophrenia.

The conversion rate for a first episode of drug induced psychosis to bipolar disorder or schizophrenia is lower, with 30% of people converting to either bipolar disorder or schizophrenia. NICE makes no distinction between substance-induced psychosis and any other form of psychosis. The rate of conversion differs for different classes of drugs.

Pharmacological options for the specific treatment of FEP have been discussed in recent reviews. The goals of treatment for FEP include reducing symptoms and potentially improving long-term treatment outcomes. Randomized clinical trials have provided evidence for the efficacy of antipsychotic drugs in achieving the former goal, with first-generation and second generation antipsychotics showing about equal efficacy. The evidence that early treatment has a favorable effect on long-term outcomes is equivocal.

Recurrent psychotic episodes
Placebo-controlled trials of both first- and second-generation antipsychotic drugs consistently demonstrate the superiority of active drugs over placebos in suppressing psychotic symptoms. A large meta-analysis of 38 trials of antipsychotic drugs in schizophrenia with acute psychotic episodes showed an effect size of about 0.5. There is little or no difference in efficacy among approved antipsychotic drugs, including both first- and second-generation agents. The efficacy of such drugs is suboptimal. Few patients achieve complete resolution of symptoms. Response rates, calculated using various cutoff values for symptom reduction, are low, and their interpretation is complicated by high placebo response rates and selective publication of clinical trial results.

Maintenance therapy
The majority of patients treated with an antipsychotic drug will experience a response within four weeks. The goals of continuing treatment are to maintain suppression of symptoms, prevent relapse, improve quality of life, and support engagement in psychosocial therapy.

Maintenance therapy with antipsychotic drugs is clearly superior to placebo in preventing relapse but is associated with weight gain, movement disorders, and high dropout rates. A 3-year trial following persons receiving maintenance therapy after an acute psychotic episode found that 33% obtained long-lasting symptom reduction, 13% achieved remission, and only 27% experienced satisfactory quality of life. The effect of relapse prevention on long term outcomes is uncertain, as historical studies show little difference in long term outcomes before and after the introduction of antipsychotic drugs.

While maintenance therapy clearly reduces the rate of relapses requiring hospitalization, a large observational study in Finland found that, in people that eventually discontinued antipsychotics, the risk of being hospitalized again for a mental health problem or dying increased the longer they were dispensed (and presumably took) antipsychotics prior to stopping therapy. If people did not stop taking antipsychotics, they remained at low risk for relapse and hospitalization compared to those that did. The authors speculated that the difference may be because the people that discontinued treatment after a longer time had more severe mental illness than those that discontinued antipsychotic therapy sooner.

A significant challenge in the use of antipsychotic drugs for the prevention of relapse is the poor rate of adherence. In spite of the relatively high rates of adverse effects associated with these drugs, some evidence, including higher dropout rates in placebo arms compared to treatment arms in randomized clinical trials, suggests that most patients who discontinue treatment do so because of suboptimal efficacy. If someone experiences psychotic symptoms due to nonadherence, they may be compelled to receive treatment through a process called involuntary commitment, in which they can be forced to accept treatment (including antipsychotics). A person can also be committed to treatment outside of a hospital, called outpatient commitment.

Antipsychotics in long-acting injectable (LAI), or "depot", form have been suggested as a method of decreasing medication nonadherence (sometimes also called non-compliance). NICE advises LAIs be offered to patients when preventing covert, intentional nonadherence is a clinical priority. LAIs are used to ensure adherence in outpatient commitment. A meta-analysis found that LAIs resulted in lower rates of rehospitalization with a hazard ratio of 0.83; however, these results were not statistically significant (the 95% confidence interval was 0.62 to 1.11).

Bipolar disorder
Antipsychotics are routinely used, often in conjunction with mood stabilizers such as lithium/valproate, as a first-line treatment for manic and mixed episodes associated with bipolar disorder. The reason for this combination is the therapeutic delay of the aforementioned mood stabilizers (for valproate therapeutic effects are usually seen around five days after treatment is commenced whereas lithium usually takes at least a week before the full therapeutic effects are seen) and the comparatively rapid antimanic effects of antipsychotic drugs. The antipsychotics have a documented efficacy when used alone in acute mania/mixed episodes.

At least five atypical antipsychotics (lumateperone, cariprazine, lurasidone, olanzapine, and quetiapine ) have also been found to possess efficacy in the treatment of bipolar depression as a monotherapy, whereas only olanzapine and quetiapine have been proven to be effective broad-spectrum (i.e., against all three types of relapse—manic, mixed and depressive) prophylactic (or maintenance) treatments in patients with bipolar disorder. A recent Cochrane review also found that olanzapine had a less favourable risk/benefit ratio than lithium as a maintenance treatment for bipolar disorder.

The American Psychiatric Association and the UK National Institute for Health and Care Excellence recommend antipsychotics for managing acute psychotic episodes in schizophrenia or bipolar disorder, and as a longer-term maintenance treatment for reducing the likelihood of further episodes. They state that response to any given antipsychotic can be variable so that trials may be necessary, and that lower doses are to be preferred where possible. A number of studies have looked at levels of "compliance" or "adherence" with antipsychotic regimes and found that discontinuation (stopping taking them) by patients is associated with higher rates of relapse, including hospitalization.

Dementia
Psychosis and agitation develop in as many as 80 percent of people living in nursing homes. Despite a lack of FDA approval and black-box warnings, atypical antipsychotics are very often prescribed to people with dementia. An assessment for an underlying cause of behavior is needed before prescribing antipsychotic medication for symptoms of dementia. Antipsychotics in old age dementia showed a modest benefit compared to placebo in managing aggression or psychosis, but this is combined with a fairly large increase in serious adverse events. Thus, antipsychotics should not be used routinely to treat dementia with aggression or psychosis, but may be an option in a few cases where there is severe distress or risk of physical harm to others. Psychosocial interventions may reduce the need for antipsychotics. In 2005, the FDA issued an advisory warning of an increased risk of death when atypical antipsychotics are used in dementia. In the subsequent 5 years, the use of atypical antipsychotics to treat dementia decreased by nearly 50%.

Major depressive disorder
A number of atypical antipsychotics have some benefits when used in addition to other treatments in major depressive disorder. Aripiprazole, quetiapine extended-release, and olanzapine (when used in conjunction with fluoxetine) have received the Food and Drug Administration (FDA) labelling for this indication. There is, however, a greater risk of side effects with their use compared to using traditional antidepressants. The greater risk of serious side effects with antipsychotics is why, e.g., quetiapine was denied approval as monotherapy for major depressive disorder or generalized anxiety disorder, and instead was only approved as an adjunctive treatment in combination with traditional antidepressants.

A recent study on the use of antipychotics in unipolar depression concluded that the use of those drugs in addition to antidepressants alone leads to a worse disease outcome. This effect is especially pronounced in younger patients with psychotic unipolar depression. Considering the wide use of such combination therapies, further studies on the side effects of antipychotics as an add-on therapy are warranted.

Other
Global antipsychotic utilization has seen a steady growth since the introduction of atypical (second-generation) antipsychotics and this is ascribed to off-label use for many other unapproved disorders. Besides the above uses antipsychotics may be used for obsessive–compulsive disorder, post-traumatic stress disorder, personality disorders, Tourette syndrome, autism and agitation in those with dementia. Evidence however does not support the use of atypical antipsychotics in eating disorders or personality disorder. The atypical antipsychotic risperidone may be useful for obsessive–compulsive disorder. The use of low doses of antipsychotics for insomnia, while common, is not recommended as there is little evidence of benefit as well as concern regarding adverse effects. Some of the more serious adverse effects may also occur at the low doses used, such as dyslipidemia and neutropenia, and a recent network meta-analysis of 154 double-blind, randomized controlled trials of drug therapies vs. placebo for insomnia in adults found that quetiapine did not demonstrated any short-term benefits in sleep quality. Low dose antipsychotics may also be used in treatment of impulse-behavioural and cognitive-perceptual symptoms of borderline personality disorder. Despite the lack of evidence supporting the benefit of antipsychotics in people with personality disorders, 1 in 4 who do not have a serious mental illness are prescribed them in UK primary care. Many people receive these medication for over a year, contrary to NICE guidelines.

In children they may be used in those with disruptive behavior disorders, mood disorders and pervasive developmental disorders or intellectual disability. Antipsychotics are only weakly recommended for Tourette syndrome, because although they are effective, side effects are common. The situation is similar for those on the autism spectrum. Much of the evidence for the off-label use of antipsychotics (for example, for dementia, OCD, PTSD, personality disorders, Tourette's) was of insufficient scientific quality to support such use, especially as there was strong evidence of increased risks of stroke, tremors, significant weight gain, sedation, and gastrointestinal problems. A UK review of unlicensed usage in children and adolescents reported a similar mixture of findings and concerns. A survey of children with pervasive developmental disorder found that 16.5% were taking an antipsychotic drug, most commonly for irritability, aggression, and agitation. Both risperidone and aripiprazole have been approved by the US FDA for the treatment of irritability in autistic children and adolescents. A review in the UK found that the use of antipsychotics in England doubled between 2000 and 2019. Children were prescribed antipsychotics for conditions for which there is no approval, such as autism.

Aggressive challenging behavior in adults with intellectual disability is often treated with antipsychotic drugs despite lack of an evidence base. A recent randomized controlled trial, however, found no benefit over placebo and recommended that the use of antipsychotics in this way should no longer be regarded as an acceptable routine treatment.

Antipsychotics may be an option, together with stimulants, in people with ADHD and aggressive behavior when other treatments have not worked. They have not been found to be useful for the prevention of delirium among those admitted to hospital.

Typicals vs atypicals
Aside from reduced extrapyramidal symptoms, and with the clear exception of clozapine, it is unclear whether the atypical (second-generation) antipsychotics offer advantages over older, first generation antipsychotics. Amisulpride, olanzapine, risperidone and clozapine may be more effective but are associated with greater side effects. Typical antipsychotics have equal drop-out and symptom relapse rates to atypicals when used at low to moderate dosages.

Clozapine is an effective treatment for those who respond poorly to other drugs ("treatment-resistant" or "refractory" schizophrenia), but it has the potentially serious side effect of agranulocytosis (lowered white blood cell count) in less than 4% of people.

Due to bias in the research the accuracy of comparisons of atypical antipsychotics is a concern.

In 2005, a US government body, the National Institute of Mental Health published the results of a major independent study (the CATIE project). No other atypical studied (risperidone, quetiapine, and ziprasidone) did better than the first-generation antipsychotic perphenazine on the measures used, nor did they produce fewer adverse effects than the typical antipsychotic perphenazine, although more patients discontinued perphenazine owing to extrapyramidal effects compared to the atypical agents (8% vs. 2% to 4%). This is significant because any patient with tardive dyskinesia was specifically excluded from randomization to perphenazine; i.e., in the CATIE study the patient cohort randomized to receive perphenazne was at lower risk of having extrapyramidal symptoms.

Atypical antipsychotics do not appear to lead to improved rates of medication adherence compared to typical antipsychotics.

Many researchers question the first-line prescribing of atypicals over typicals, and some even question the distinction between the two classes. In contrast, other researchers point to the significantly higher risk of tardive dyskinesia and other extrapyramidal symptoms with the typicals and for this reason alone recommend first-line treatment with the atypicals, notwithstanding a greater propensity for metabolic adverse effects in the latter. The UK government organization NICE recently revised its recommendation favoring atypicals, to advise that the choice should be an individual one based on the particular profiles of the individual drug and on the patient's preferences.

The re-evaluation of the evidence has not necessarily slowed the bias toward prescribing the atypicals.

Adverse effects
Generally, more than one antipsychotic drug should not be used at a time because of increased adverse effects., which cites

Some atypicals are associated with considerable weight gain, diabetes and the risk of metabolic syndrome. Unwanted side effects cause people to stop treatment, resulting in relapses. Risperidone (atypical) has a similar rate of extrapyramidal symptoms to haloperidol (typical). A rare but potentially lethal condition of neuroleptic malignant syndrome (NMS) has been associated with the use of antipsychotics. Through its early recognition, and timely intervention rates have declined. However, an awareness of the syndrome is advised to enable intervention. Another less rare condition of tardive dyskinesia can occur due to long-term use of antipsychotics, developing after months or years of use. It is more often reported with use of typical antipsychotics. Very rarely antipsychotics may cause tardive psychosis.

Clozapine is associated with side effects that include weight gain, tiredness, and hypersalivation. More serious adverse effects include seizures, NMS, neutropenia, and agranulocytosis (lowered white blood cell count) and its use needs careful monitoring.

Clozapine is also associated with thromboembolism (including pulmonary embolism), myocarditis, and cardiomyopathy. A systematic review of clozapine-associated pulmonary embolism indicates that this adverse effect can often be fatal, and that it has an early onset, and is dose-dependent. The findings advised the consideration of using a prevention therapy for venous thromboembolism after starting treatment with clozapine, and continuing this for six months. Constipation is three times more likely to occur with the use of clozapine, and severe cases can lead to ileus and bowel ischemia resulting in many fatalities. Very rare clozapine adverse effects include periorbital edema due to several possible mechanisms (e.g., inhibition of platelet-derived growth factor receptors leading to increased vascular permeability, antagonism of renal dopamine receptors with electrolyte and fluid imbalance and immune-mediated hypersensitivity reactions).

However, the risk of serious adverse effects from clozapine is low, and there are the beneficial effects to be gained of a reduced risk of suicide, and aggression. Typical antipsychotics and atypical risperidone can have a side effect of sexual dysfunction. Clozapine, olanzapine, and quetiapine are associated with beneficial effects on sexual functioning helped by various psychotherapies.

By rate
Common (≥ 1% and up to 50% incidence for most antipsychotic drugs) adverse effects of antipsychotics include:
 * Dysphoria and apathy (due to dopamine receptor blockade)
 * Sedation (particularly common with asenapine, clozapine, olanzapine, quetiapine, chlorpromazine and zotepine )
 * Headaches
 * Dizziness
 * Diarrhea
 * Anxiety
 * Extrapyramidal side effects (particularly common with first-generation antipsychotics), which include:
 * - Akathisia, an often distressing sense of inner restlessness.
 * - Dystonia, an abnormal muscle contraction
 * - Pseudoparkinsonism, symptoms that are similar to what people with Parkinson's disease experience, including tremulousness and drooling

 * Hyperprolactinaemia (rare for those treated with clozapine, quetiapine and aripiprazole ), which can cause:
 * - Galactorrhoea, the unusual secretion of breast milk.
 * - Gynaecomastia, abnormal growth of breast tissue
 * - Sexual dysfunction (in both sexes)
 * - Osteoporosis

 * Orthostatic hypotension
 * Weight gain (particularly prominent with clozapine, olanzapine, quetiapine and zotepine )
 * Anticholinergic side-effects (common for olanzapine, clozapine; less likely on risperidone ) such as:
 * - Blurred vision
 * - Constipation
 * - Dry mouth (although hypersalivation may also occur)
 * - Reduced perspiration

 * Tardive dyskinesia appears to be more frequent with high-potency first-generation antipsychotics, such as haloperidol, and tends to appear after chronic and not acute treatment. It is characterized by slow (hence the tardive) repetitive, involuntary and purposeless movements, most often of the face, lips, legs, or torso, which tend to resist treatment and are frequently irreversible. The rate of appearance of TD is about 5% per year of use of antipsychotic drug (whatever the drug used)
 * Breast cancer: a systematic review and meta-analysis of observational studies with over 2 million individuals estimated an association between antipsychotic use and breast cancer by over 30%.

Rare/Uncommon (<1% incidence for most antipsychotic drugs) adverse effects of antipsychotics include:
 * Blood dyscrasias (e.g., agranulocytosis, leukopenia, and neutropaenia), which is more common in patients on clozapine.
 * Metabolic syndrome and other metabolic problems such as type II diabetes mellitus — particularly common with clozapine, olanzapine and zotepine. In American studies African Americans appeared to be at a heightened risk for developing type II diabetes mellitus. Evidence suggests that females are more sensitive to the metabolic side effects of first-generation antipsychotic drugs than males. Metabolic adverse effects appear to be mediated by the following mechanisms:
 * - Causing weight gain by antagonizing the histamine H1 and serotonin 5-HT2C receptors and perhaps by interacting with other neurochemical pathways in the central nervous system.

 * Neuroleptic malignant syndrome, a potentially fatal condition characterized by:
 * - Autonomic instability, which can manifest with tachycardia, nausea, vomiting, diaphoresis, etc.
 * - Hyperthermia — elevated body temperature.
 * - Mental status change (confusion, hallucinations, coma, etc.)
 * - Muscle rigidity
 * - Laboratory abnormalities (e.g., elevated creatine kinase, reduced iron plasma levels, electrolyte abnormalities, etc.)

 * Pancreatitis
 * QT interval prolongation — more prominent in those treated with amisulpride, pimozide, sertindole, thioridazine and ziprasidone.
 * Torsades de pointes
 * Seizures, particularly in people treated with chlorpromazine and clozapine.
 * Thromboembolism
 * Myocardial infarction
 * Stroke
 * Pisa syndrome

Long-term effects
Some studies have found decreased life expectancy associated with the use of antipsychotics, and argued that more studies are needed. Antipsychotics may also increase the risk of early death in individuals with dementia. Antipsychotics typically worsen symptoms in people with depersonalisation disorder. Antipsychotic polypharmacy (prescribing two or more antipsychotics at the same time for an individual) is a common practice but not evidence-based or recommended, and there are initiatives to curtail it. Similarly, the use of excessively high doses (often the result of polypharmacy) continues despite clinical guidelines and evidence indicating that it is usually no more effective but is usually more harmful. A meta-analysis of observational studies with over two million individuals has suggested a moderate association of antipsychotic use with breast cancer.

Loss of grey matter and other brain structural changes over time are observed amongst people diagnosed with schizophrenia. Meta-analyses of the effects of antipsychotic treatment on grey matter volume and the brain's structure have reached conflicting conclusions. A 2012 meta-analysis concluded that grey matter loss is greater in patients treated with first generation antipsychotics relative to those treated with atypicals, and hypothesized a protective effect of atypicals as one possible explanation. A second meta-analysis suggested that treatment with antipsychotics was associated with increased grey matter loss. Animal studies found that monkeys exposed to both first- and second-generation antipsychotics experience significant reduction in brain volume, resulting in an 8-11% reduction in brain volume over a 17–27 month period.

The National Association of State Mental Health Program Directors said that antipsychotics are not interchangeable and it is recommend including trying at least one weight-neutral treatment for those patients with potential metabolic issues.

Subtle, long-lasting forms of akathisia are often overlooked or confused with post-psychotic depression, in particular when they lack the extrapyramidal aspect that psychiatrists have been taught to expect when looking for signs of akathisia.

Adverse effect on cognitive function  and increased risk of death in people with dementia along with worsening of symptoms has been described in the literature.

Discontinuation
The British National Formulary recommends a gradual withdrawal when discontinuing antipsychotics to avoid acute withdrawal syndrome or rapid relapse. Symptoms of withdrawal commonly include nausea, vomiting, and loss of appetite. Other symptoms may include restlessness, increased sweating, and trouble sleeping. Less commonly there may be a feeling of the world spinning, numbness, or muscle pains. Symptoms generally resolve after a short period of time.

There is tentative evidence that discontinuation of antipsychotics can result in psychosis. It may also result in recurrence of the condition that is being treated. Rarely tardive dyskinesia can occur when the medication is stopped.

Unexpected psychotic episodes have been observed in patients withdrawing from clozapine. This is referred to as supersensitivity psychosis, not to be equated with tardive dyskinesia.

Tardive dyskinesia may abate during withdrawal from the antipsychotic agent, or it may persist.

Withdrawal effects may also occur when switching a person from one antipsychotic to another, (it is presumed due to variations of potency and receptor activity). Such withdrawal effects can include cholinergic rebound, an activation syndrome, and motor syndromes including dyskinesias. These adverse effects are more likely during rapid changes between antipsychotic agents, so making a gradual change between antipsychotics minimises these withdrawal effects. The British National Formulary recommends a gradual withdrawal when discontinuing antipsychotic treatment to avoid acute withdrawal syndrome or rapid relapse. The process of cross-titration involves gradually increasing the dose of the new medication while gradually decreasing the dose of the old medication.

City and Hackney Clinical Commissioning Group found more than 1,000 patients in their area in July 2019 who had not had regular medication reviews or health checks because they were not registered as having serious mental illness. On average they had been taking these drugs for six years. If this is typical of practice in England more than 100,000 patients are probably in the same position.

List of agents

Clinically used antipsychotic medications are listed below by drug group. Trade names appear in parentheses. A 2013 review has stated that the division of antipsychotics into first and second generation is perhaps not accurate.

Notes:

''† indicates drugs that are no longer (or were never) marketed in English-speaking countries. ''

''‡ denotes drugs that are no longer (or were never to begin with) marketed in the United States. Some antipsychotics are not firmly placed in either first-generation or second-generation classes.''

# denotes drugs that have been withdrawn worldwide.

Butyrophenones

 * Benperidol‡
 * Bromperidol†
 * Droperidol‡
 * Haloperidol (Haldol)
 * Moperone (discontinued)†
 * Pipamperone (discontinued)†
 * Timiperone †

Diphenylbutylpiperidines

 * Fluspirilene ‡
 * Penfluridol ‡
 * Pimozide

Phenothiazines

 * Acepromazine † — although it is mostly used in veterinary medicine.
 * Chlorpromazine (Thorazine)
 * Cyamemazine †
 * Dixyrazine †
 * Fluphenazine
 * Levomepromazine‡
 * Mesoridazine (discontinued)†
 * Perazine
 * Pericyazine‡
 * Perphenazine
 * Pipotiazine ‡
 * Prochlorperazine
 * Promazine (discontinued)
 * Promethazine
 * Prothipendyl †
 * Thioproperazine‡ (only English-speaking country it is available in is Canada)
 * Thioridazine (discontinued)
 * Trifluoperazine
 * Triflupromazine (discontinued)†

Thioxanthenes

 * Chlorprothixene †
 * Clopenthixol
 * Flupentixol ‡
 * Thiothixene
 * Zuclopenthixol ‡

Disputed/unknown
This category is for drugs that have been called both first and second-generation, depending on the literature being used.

Benzamides

 * Sulpiride ‡
 * Sultopride †
 * Veralipride †

Tricyclics

 * Carpipramine †
 * Clocapramine †
 * Clorotepine †
 * Clotiapine ‡
 * Loxapine
 * Mosapramine †

Others

 * Molindone #

Benzamides

 * Amisulpride (Socian) ‡ – Selective dopamine antagonist. Higher doses (greater than 400 mg) act upon post-synaptic dopamine receptors resulting in a reduction in the positive symptoms of schizophrenia, such as psychosis. Lower doses, however, act upon dopamine autoreceptors, resulting in increased dopamine transmission, improving the negative symptoms of schizophrenia. Lower doses of amisulpride have also been shown to have antidepressant and anxiolytic effects in non-schizophrenic patients, leading to its use in dysthymia and social phobias.
 * Nemonapride † – Used in Japan.
 * Remoxipride # – Has a risk of causing aplastic anaemia and, hence, has been withdrawn from the market worldwide. It has also been found to possess relatively low (virtually absent) potential to induce hyperprolactinaemia and extrapyramidal symptoms, likely attributable to its comparatively weak binding to (and, hence, rapid dissociation from) the D2 receptor.
 * Sultopride – An atypical antipsychotic of the benzamide chemical class used in Europe, Japan, and Hong Kong for the treatment of schizophrenia. It was launched by Sanofi-Aventis in 1976. Sultopride acts as a selective D2 and D3 receptor antagonist.

Benzisoxazoles/benzisothiazoles

 * Iloperidone (Fanapt) – Approved by the US FDA in 2009, it is fairly well tolerated, although hypotension, dizziness, and somnolence were very common side effects. Has not received regulatory approval in other countries, however.
 * Paliperidone (Invega) – Primary, active metabolite of risperidone that was approved in 2006.
 * Perospirone † – Has a higher incidence of extrapyramidal side effects than other atypical antipsychotics.
 * Risperidone (Risperdal) – Divided dosing is recommended until initial titration is completed, at which time the drug can be administered once daily. Used off-label to treat Tourette syndrome and anxiety disorder.
 * Ziprasidone (Geodon) – Approved in 2004 to treat bipolar disorder. Side-effects include a prolonged QT interval in the heart, which can be dangerous for patients with heart disease or those taking other drugs that prolong the QT interval.
 * Lurasidone (Latuda) – Approved by the US FDA for schizophrenia and bipolar depression, and for use as schizophrenia treatment in Canada.

Butyrophenones

 * Melperone † – Only used in a few European countries. No English-speaking country has licensed it to date.
 * Lumateperone (Caplyta)

Tricyclics

 * Asenapine (Saphris) – Of the dibenzo-oxepino pyrrole class of atypical antipsychotics. Used for the treatment of schizophrenia and acute mania associated with bipolar disorder.
 * Clozapine (Clozaril) – Of the dibenzodiazepine class of atypical antipsychotics. Requires routine laboratory monitoring of complete blood counts every one to four weeks due to the risk of agranulocytosis. It has unparalleled efficacy in the treatment of treatment-resistant schizophrenia.
 * Olanzapine (Zyprexa) – Of the theienobenzodiazepine class of atypical antipsychotics. Used to treat psychotic disorders including schizophrenia, acute manic episodes, and maintenance of bipolar disorder. Used as an adjunct to antidepressant therapy, either alone or in combination with fluoxetine as Symbyax.
 * Quetiapine (Seroquel) – Of the dibenzothiazepine class of atypical antipsychotics. Used primarily to treat bipolar disorder and schizophrenia. Also used and licensed in a few countries (including Australia, the United Kingdom and the United States) as an adjunct to antidepressant therapy in patients with major depressive disorder. It's the only antipsychotic that's demonstrated efficacy as a monotherapy for the treatment of major depressive disorder and bipolar disorder (it treats mixed mood swings alone). It indirectly serves as a norepinephrine reuptake inhibitor by means of its active metabolite, norquetiapine.
 * Zotepine – Of the dibenzothiepin class of atypical antipsychotic indicated for acute and chronic schizophrenia. It is still used in Japan and was once used in Germany but it was discontinued.†

Others

 * Blonanserin – Approved by the PMDA in 2008. Used in Japan and South Korea.
 * Pimavanserin – A selective 5-HT2A receptor antagonist approved for the treatment of Parkinson's disease psychosis in 2016.
 * Sertindole ‡ – Developed by the Danish pharmaceutical company H. Lundbeck. Like the other atypical antipsychotics, it is believed to have antagonist activity at dopamine and serotonin receptors in the brain.

Third-generation
Third generation antipsychotics are recognized as demonstrating D2 receptor partial agonism as opposed to the D2 and 5HT-2A receptor antagonism of second-generation (atypical) antipsychotics and D2 antagonism of first-generation (typical) antipsychotics.

Benzisoxazoles/benzisothiazoles

 * Lumateperone (Caplyta) – In December 2019, lumateperone, a presynaptic D2 receptor partial agonist and postsynaptic D2 receptor antagonist, received its first global approval in the USA for the treatment of schizophrenia in adults. In 2020 and 2021 FDA approved for depressive episodes associated with bipolar I or II disorder in adults, as monotherapy and as adjunctive therapy with lithium or valproate.

Phenylpiperazines/quinolinones/benzoxazinones

 * Aripiprazole (Abilify) - Partial agonist at the D2 receptor. Considered the prototypical third-generation antipsychotic.
 * Aripiprazole lauroxil (Abilify Maintena) – Long-acting version of aripiprazole for injection.
 * Brexpiprazole (Rexulti) – Partial agonist of the D2 receptor. Successor of aripiprazole.
 * Brilaroxazine – A D2/3/4 and 5-HT1A partial agonist and 5-HT2A/2B/7 antagonist
 * Cariprazine (Vraylar, Reagila) – A D3-preferring D2/3 partial agonist.

Mechanism of action
Antipsychotic drugs such as haloperidol and chlorpromazine tend to block dopamine D2 receptors in the dopaminergic pathways of the brain. This means that dopamine released in these pathways has less effect. Excess release of dopamine in the mesolimbic pathway has been linked to psychotic experiences. Decreased dopamine release in the prefrontal cortex, and excess dopamine release in other pathways, are associated with psychotic episodes in schizophrenia and bipolar disorder.

In addition to the antagonistic effects of dopamine, antipsychotics (in particular atypical neuroleptics) also antagonize 5-HT2A receptors. Different alleles of the 5-HT2A receptor have been associated with schizophrenia and other psychoses, including depression. Higher concentrations of 5-HT2A receptors in cortical and subcortical areas, in particular in the right caudate nucleus have been historically recorded.

Typical antipsychotics are not particularly selective and also block dopamine receptors in the mesocortical pathway, tuberoinfundibular pathway, and the nigrostriatal pathway. Blocking D2 receptors in these other pathways is thought to produce some unwanted side effects that the typical antipsychotics can produce (see above). They were commonly classified on a spectrum of low potency to high potency, where potency referred to the ability of the drug to bind to dopamine receptors, and not to the effectiveness of the drug. High-potency antipsychotics such as haloperidol, in general, have doses of a few milligrams and cause less sleepiness and calming effects than low-potency antipsychotics such as chlorpromazine and thioridazine, which have dosages of several hundred milligrams. The latter have a greater degree of anticholinergic and antihistaminergic activity, which can counteract dopamine-related side-effects.

Atypical antipsychotic drugs have a similar blocking effect on D2 receptors; however, most also act on serotonin receptors, especially 5-HT2A and 5-HT2C receptors. Both clozapine and quetiapine appear to bind just long enough to elicit antipsychotic effects but not long enough to induce extrapyramidal side effects and prolactin hypersecretion. 5-HT2A antagonism increases dopaminergic activity in the nigrostriatal pathway, leading to a lowered extrapyramidal side effect liability among the atypical antipsychotics.

Through the ability of most antipsychotics to antagonize 5-HT2A serotonin pathways enabling a sensitisation of postsynaptic serotonin receptors, MDMA exposure can be more intense because it has more excitatory receptors to activate. The same effect can be observed with the D2 antagonizing with normal amphetamine (with this just being hypothetical as there is the fact that antipsychotics sensitize receptors, with exact these postsynaptic receptors (5-HT2A, D2) being flooded by the respective neurotransmitter (serotonine, dopamine) from amphetamine exposure).

History

The original antipsychotic drugs were happened upon largely by chance and then tested for their effectiveness. The first, chlorpromazine, was developed as a surgical anesthetic. It was first used on psychiatric patients because of its powerful calming effect; at the time it was regarded as a non-permanent "pharmacological lobotomy". Lobotomy at the time was used to treat many behavioral disorders, including psychosis, although its effect was to markedly reduce behavior and mental functioning of all types. However, chlorpromazine proved to reduce the effects of psychosis in a more effective and specific manner than lobotomy, even though it was known to be capable of causing severe sedation. The underlying neurochemistry involved has since been studied in detail, and subsequent antipsychotic drugs have been developed by rational drug design.

The discovery of chlorpromazine's psychoactive effects in 1952 led to further research that resulted in the development of antidepressants, anxiolytics, and the majority of other drugs now used in the management of psychiatric conditions. In 1952, Henri Laborit described chlorpromazine only as inducing indifference towards what was happening around them in nonpsychotic, nonmanic patients, and Jean Delay and Pierre Deniker described it as controlling manic or psychotic agitation. The former claimed to have discovered a treatment for agitation in anyone, and the latter team claimed to have discovered a treatment for psychotic illness.

Until the 1970s there was considerable debate within psychiatry on the most appropriate term to use to describe the new drugs. In the late 1950s the most widely used term was "neuroleptic", followed by "major tranquilizer" and then "ataraxic". The first recorded use of the term tranquilizer dates from the early nineteenth century. In 1953 Frederik F. Yonkman, a chemist at the Swiss-based Cibapharmaceutical company, first used the term tranquilizer to differentiate reserpine from the older sedatives. The word neuroleptic was coined in 1955 by Delay and Deniker after their discovery (1952) of the antipsychotic effects of chlorpromazine. It is derived from the "νεῦρον" (neuron, originally meaning "sinew" but today referring to the nerves) and "λαμβάνω" (lambanō, meaning "take hold of"). Thus, the word means taking hold of one's nerves. It was often taken to refer also to common side effects such as reduced activity in general, as well as lethargy and impaired motor control. Although these effects are unpleasant and in some cases harmful, they were at one time, along with akathisia, considered a reliable sign that the drug was working. The term "ataraxy" was coined by the neurologist Howard Fabing and the classicist Alister Cameron to describe the observed effect of psychic indifference and detachment in patients treated with chlorpromazine. This term derived from the Greek adjective "ἀτάρακτος" (ataraktos), which means "not disturbed, not excited, without confusion, steady, calm". In the use of the terms "tranquilizer" and "ataractic", medical practitioners distinguished between the "major tranquilizers" or "major ataractics", which referred to drugs used to treat psychoses, and the "minor tranquilizers" or "minor ataractics", which referred to drugs used to treat neuroses. While popular during the 1950s, these terms are infrequently used today. They are being abandoned in favor of "antipsychotic", which refers to the drug's desired effects. Today, "minor tranquilizer" can refer to anxiolytic and/or hypnotic drugs such as the benzodiazepines and nonbenzodiazepines, which are useful as generally short-term management for insomnia together with cognitive behavioral therapy for insomnia. They are potentially addictive sedatives.

Antipsychotics are broadly divided into two groups, the typical or first-generation antipsychotics and the atypical or second-generation antipsychotics. The difference between first- and second-generation antipsychotics is a subject of debate. The second-generation antipsychotics are generally distinguishable by the presence of 5HT2A receptor antagonism and a corresponding lower propensity for extrapyramidal side effects compared to first-generation antipsychotics.

Terminology
The term major tranquilizer was used for older antipsychotic drugs. The term neuroleptic is often used as a synonym for antipsychotic, even though – strictly speaking – the two terms are not interchangeable. Antipsychotic drugs are a subgroup of neuroleptic drugs, because the latter have a wider range of effects.

Antipsychotics are a type of psychoactive or psychotropic medication.

Sales
Antipsychotics were once among the biggest selling and most profitable of all drugs, generating $22 billion in global sales in 2008. By 2003 in the US, an estimated 3.21 million patients received antipsychotics, worth an estimated $2.82 billion. Over 2/3 of prescriptions were for the newer, more expensive atypicals, each costing on average $164 per year, compared to $40 for the older types. By 2008, sales in the US reached $14.6 billion, the biggest selling drugs in the US by therapeutic class.

In the five years since July 2017 the number of antipsychotic medicines dispensed in the community in the United Kingdom has increased by 11.2%. There have also been substantial price rises. Risperidone 6 mg tablets, the largest, increased from £3.09 in July 2017 to £41.16 in June 2022. The NHS is spending an additional £33 million annually on antipsychotics. Haloperidol 500 microgram tablets constituted £14.3 million of this.

Overprescription
Antipsychotics in the nursing home population are often overprescribed, often for the purposes of making it easier to handle dementia patients. Federal efforts to reduce the use of antipsychotics in US nursing homes has led to a nationwide decrease in their usage in 2012.

Legal
Antipsychotics are sometimes administered as part of compulsory psychiatric treatment via inpatient (hospital) commitment or outpatient commitment.

Formulations
They may be administered orally or, in some cases, through long-acting (depot) injections administered in the dorsgluteal, ventrogluteal or deltoid muscle. Short-acting parenteral formulations also exist, which are generally reserved for emergencies or when oral administration is otherwise impossible. The oral formulations include immediate release, extended release, and orally disintegrating products (which are not sublingual, and can help ensure that medications are swallowed instead of "cheeked"). Sublingual products (e.g., asenapine) also exist, which must be held under the tongue for absorption. The first transdermal formulation of an antipsychotic (transdermal asenapine, marketed as Secuado), was FDA-approved in 2019.

Recreational use
Certain second-generation antipsychotics are misused or abused for their sedative, tranquilizing, and (paradoxically) "hallucinogenic" effects. The most commonly implicated second-generation antipsychotic is quetiapine. In case reports, quetiapine has been abused in doses taken by mouth (which is how the drug is available from the manufacturer), but also crushed and insufflated or mixed with water for injection into a vein. Olanzapine, another sedating second-generation antipsychotic, has also been misused for similar reasons. There is no standard treatment for antipsychotic abuse, though switching to a second-generation antipsychotic with less abuse potential (e.g., aripiprazole) has been used.

Controversy
Joanna Moncrieff has argued that antipsychotic drug treatment is often undertaken as a means of control rather than to treat specific symptoms experienced by the patient.

Use of this class of drugs has a history of criticism in residential care. As the drugs used can make patients calmer and more compliant, critics claim that the drugs can be overused. Outside doctors can feel under pressure from care home staff. In an official review commissioned by UK government ministers it was reported that the needless use of antipsychotic medication in dementia care was widespread and was linked to 1800 deaths per year. In the US, the government has initiated legal action against the pharmaceutical company Johnson & Johnson for allegedly paying kickbacks to Omnicare to promote its antipsychotic risperidone (Risperdal) in nursing homes.

There has also been controversy about the role of pharmaceutical companies in marketing and promoting antipsychotics, including allegations of downplaying or covering up adverse effects, expanding the number of conditions or illegally promoting off-label usage; influencing drug trials (or their publication) to try to show that the expensive and profitable newer atypicals were superior to the older cheaper typicals that were out of patent. Following charges of illegal marketing, settlements by two large pharmaceutical companies in the US set records for the largest criminal fines ever imposed on corporations. One case involved Eli Lilly and Company's antipsychotic Zyprexa, and the other involved Bextra. In the Bextra case, the government also charged Pfizer with illegally marketing another antipsychotic, Geodon. In addition, AstraZeneca faces numerous personal-injury lawsuits from former users of Seroquel (quetiapine), amidst federal investigations of its marketing practices. By expanding the conditions for which they were indicated, Astrazeneca's Seroquel and Eli Lilly's Zyprexa had become the biggest selling antipsychotics in 2008 with global sales of $5.5 billion and $5.4 billion respectively.

Harvard University medical professor Joseph Biederman conducted research on bipolar disorder in children that led to an increase in such diagnoses. A 2008 Senate investigation found that Biederman also received $1.6 million in speaking and consulting fees between 2000 and 2007, some of them undisclosed to Harvard, from companies including makers of antipsychotic drugs prescribed for children with bipolar disorder. Johnson & Johnson gave more than $700,000 to a research center that was headed by Biederman from 2002 to 2005, where research was conducted, in part, on Risperdal, the company's antipsychotic drug. Biederman has responded saying that the money did not influence him and that he did not promote a specific diagnosis or treatment.

Pharmaceutical companies have also been accused of attempting to set the mental health agenda through activities such as funding consumer advocacy groups.

Special populations
It is recommended that persons with dementia who exhibit behavioral and psychological symptoms should not be given antipsychotics before trying other treatments., which cites
 * When taking antipsychotics this population has increased risk of cerebrovascular effects, parkinsonism or extrapyramidal symptoms, sedation, confusion and other cognitive adverse effects, weight gain, and increased mortality. Physicians and caretakers of persons with dementia should try to address symptoms including agitation, aggression, apathy, anxiety, depression, irritability, and psychosis with alternative treatments whenever antipsychotic use can be replaced or reduced. Elderly persons often have their dementia treated first with antipsychotics and this is not the best management strategy., which cites
 * When taking antipsychotics this population has increased risk of cerebrovascular effects, parkinsonism or extrapyramidal symptoms, sedation, confusion and other cognitive adverse effects, weight gain, and increased mortality. Physicians and caretakers of persons with dementia should try to address symptoms including agitation, aggression, apathy, anxiety, depression, irritability, and psychosis with alternative treatments whenever antipsychotic use can be replaced or reduced. Elderly persons often have their dementia treated first with antipsychotics and this is not the best management strategy., which cites
 * When taking antipsychotics this population has increased risk of cerebrovascular effects, parkinsonism or extrapyramidal symptoms, sedation, confusion and other cognitive adverse effects, weight gain, and increased mortality. Physicians and caretakers of persons with dementia should try to address symptoms including agitation, aggression, apathy, anxiety, depression, irritability, and psychosis with alternative treatments whenever antipsychotic use can be replaced or reduced. Elderly persons often have their dementia treated first with antipsychotics and this is not the best management strategy., which cites
 * When taking antipsychotics this population has increased risk of cerebrovascular effects, parkinsonism or extrapyramidal symptoms, sedation, confusion and other cognitive adverse effects, weight gain, and increased mortality. Physicians and caretakers of persons with dementia should try to address symptoms including agitation, aggression, apathy, anxiety, depression, irritability, and psychosis with alternative treatments whenever antipsychotic use can be replaced or reduced. Elderly persons often have their dementia treated first with antipsychotics and this is not the best management strategy., which cites
 * When taking antipsychotics this population has increased risk of cerebrovascular effects, parkinsonism or extrapyramidal symptoms, sedation, confusion and other cognitive adverse effects, weight gain, and increased mortality. Physicians and caretakers of persons with dementia should try to address symptoms including agitation, aggression, apathy, anxiety, depression, irritability, and psychosis with alternative treatments whenever antipsychotic use can be replaced or reduced. Elderly persons often have their dementia treated first with antipsychotics and this is not the best management strategy., which cites

license: Creative Commons - Attribution Share-Alike - https://creativecommons.org/licenses/by-sa/4.0/

title: Antipsychotic


text:
Akita

Akita (秋田) is a Japanese name and may refer to:

Places

 * 8182 Akita, a main-belt asteroid
 * Akita Castle, a Nara period fortified settlement in Akita, Japan
 * Akita Domain, also known as Kubota Domain, feudal domain in Edo period Japan
 * Akita, Kumamoto, a former town
 * Akita Prefecture, Japan
 * Akita (city)
 * Akita-Yake-Yama, a small stratovolcano in Akita Prefecture, Japan

People

 * Akita clan, a Japanese samurai clan of northern Honshū
 * Akita (surname), for people with the surname

Art, entertainment, and media

 * Akita (Ninjago), a character in Ninjago
 * "", a folk song of Akita Prefecture, Japan
 * Akita ranga, a Japanese school of painting c. 1773–1780

Companies

 * Akita Asahi Broadcasting, a Japanese broadcast network
 * Akita Bank, a Japanese regional bank
 * Akita Broadcasting System, a Japanese television and radio broadcaster
 * Akita Shoten, a Japanese publishing company
 * Akita Television, a television station in Akita, Japan

Education

 * Akita International University, a public university in Akita, Japan
 * Akita Municipal Junior College of Arts and Crafts, a municipal junior college in Akita, Japan
 * Akita Nutrition Junior College, a private university in Akita, Japan
 * Akita Prefectural University, a Japanese prefectural university in Akita, Japan
 * Akita University, a Japanese national university in Akita, Japan
 * Akita University of Art, a public university in Akita, Japan
 * Akita University of Nursing and Welfare, a private university in Ōdate, Japan

Cultural institutions

 * Akita Museum of Art, an art museum in Akita, Japan
 * Akita Museum of Modern Art, a museum in Yokote, Akita Prefecture, Japan
 * Akita Omoriyama Zoo, a municipal zoo in Akita, Japan
 * Akita Prefectural Museum, a prefectural museum in Akita, Japan
 * Akita Senshū Museum of Art, a museum in Akita, Japan

Sports

 * Akita Northern Happinets, a Japanese professional basketball
 * Akita Prefectural Baseball Stadium, a baseball stadium in Akita, Japan
 * Akita Prefectural Gymnasium, a stadium in Akita, Japan
 * Blaublitz Akita, a Japanese association football team

Transportation

 * Akita Airport, a regional/second class airport in Akita, Japan
 * Akita Expressway, a national expressway in Japan
 * Akita Nairiku Line, a Japanese railway line
 * Akita Relay, a former limited express train service
 * Akita Rinkai Railway Line, a Japanese freight-only railway line
 * Akita Shinkansen, a mini-shinkansen high-speed rail line
 * Akita Station, a railway station in Akita, Japan
 * Akitashirakami Station, a JR East railway station in Happō, Yamamoto District, Akita Prefecture, Japan
 * Port of Akita, a seaport on the Sea of Japan coast of Akita Prefecture in Akita, Japan

Other uses

 * Akita (dog), a large spitz breed of dog originating from the mountainous northern regions of Japan
 * Akita Kantō, a Japanese festival celebrated from 3–7 August in Akita, Japan
 * Our Lady of Akita, Marian apparitions

title: Akita


text:
Archduke Charles, Duke of Teschen

Archduke Charles Louis John Joseph Laurentius of Austria, Duke of Teschen (Erzherzog Karl Ludwig Johann Josef Lorenz von Österreich, Herzog von Teschen; 5 September 1771 – 30 April 1847) was an Austrian field-marshal, the third son of Emperor Leopold II and his wife, Maria Luisa of Spain. He was also the younger brother of Francis II, Holy Roman Emperor. He was epileptic, but achieved respect both as a commander and as a reformer of the Austrian army. He was considered one of Napoleon's more formidable opponents and one of the greatest generals of the French Revolutionary and Napoleonic Wars.

He began his career fighting the revolutionary armies of France. Early in the wars of the First Coalition, he saw victory at Neerwinden in 1793, before being defeated at Wattignies in 1793 and Fleurus in 1794. In 1796, as chief of all Austrian forces on the Rhine, Charles defeated Jean-Baptiste Jourdan at Amberg, Würzburg and Limburg, and then won victories at Wetzlar, Emmendingen and Schliengen that forced Jean Victor Marie Moreau to withdraw across the Rhine. He also defeated opponents at Zürich, Ostrach, Stockach, and Mannheim in 1799. He reformed Austria's armies to adopt the nation-at-arms principle. In 1809, he entered the War of the Fifth Coalition and inflicted Napoleon's first major setback at Aspern-Essling, before suffering a defeat at the bloody Battle of Wagram. After Wagram, Charles saw no more significant action in the Napoleonic Wars.

As a military strategist, Charles was able to successfully execute complex and risky manoeuvres of troops. However, his contemporary Carl von Clausewitz criticised his rigidity and adherence to "geographic" strategy. Many Austrians nevertheless remember Charles as a hero of the French Revolutionary and Napoleonic Wars.

Youth and early career
Charles was born in Florence, Tuscany. His father, then Grand Duke of Tuscany, generously permitted Charles's childless aunt Archduchess Maria Christina of Austria and her husband Albert of Saxe-Teschen to adopt and raise the boy in Vienna. Charles spent his youth in Tuscany, at Vienna and in the Austrian Netherlands, where he began his career of military service in the wars of the French Revolution. He commanded a brigade at the Battle of Jemappes (1792), and in the campaign of 1793 distinguished himself at the Action of Aldenhoven and the Battle of Neerwinden. In this year he became Governor of the Habsburg Netherlands, an office he lost with the occupation of the Low Countries by the French revolutionaries in 1794. The year he became Governor he also received the army rank of lieutenant field marshal. Shortly thereafter another promotion saw him made Feldzeugmeister (equivalent of Lieutenant General). In the remainder of the war in the Low Countries he held high commands, and was present at the Battle of Fleurus (1794).

In 1795 he served on the Rhine, and in the following year, he was entrusted with chief control of all the Austrian forces on that river. His conduct of the operations against Jourdan and Moreau in 1796 marked him out at once as one of the greatest generals in Europe. At first, falling back carefully and avoiding a decision, he finally marched away, leaving a mere screen in front of Moreau. Falling upon Jourdan, he beat him in the battles of Amberg (August), Würzburg and Limburg (September), and drove him over the Rhine with great loss. He then turned upon Moreau's army, which he defeated and forced out of Germany after the battles of Wetzlar, Emmendingen and Schliengen.

Napoleonic Wars
In 1797 he was sent to arrest the victorious march of General Bonaparte in Italy, and he conducted the retreat of the over-matched Austrians with the highest skill. In the campaign of 1799 he once more opposed Jourdan, whom he defeated in the battles of Ostrach and Stockach, following up his success by invading Switzerland and defeating Masséna in the First Battle of Zurich, after which he re-entered Germany and drove the French once more over the Rhine after winning at Mannheim in 1799.

Ill-health, however, forced him to retire to Bohemia, but he was soon recalled to undertake the task of checking Moreau's advance on Vienna. The result of the Battle of Hohenlinden had, however, foredoomed the attempt, and the archduke had to make the armistice of Steyr. His popularity was now such that the Perpetual Diet of Regensburg, which met in 1802, resolved to erect a statue in his honour and to give him the title of saviour of his country, but Charles refused both distinctions.

In the short and disastrous war of 1805 Archduke Charles commanded what was intended to be the main army in Italy, but events made Germany the decisive theatre of operations; Austria sustained defeat on the Danube, and the archduke was defeated by Massena in the Battle of Caldiero. With the conclusion of peace he began his active work of army reorganisation, which was first tested on the field in 1809.

In 1806 Francis II (now Francis I of Austria) named the Archduke Charles, already a field marshal, as Commander in Chief of the Austrian army and Head of the Council of War. Supported by the prestige of being the only general who had proved capable of defeating the French, he promptly initiated a far-reaching scheme of reform, which replaced the obsolete methods of the 18th century. The chief characteristics of the new order were the adoption of the nation in arms principle and the adoption of French war organization and tactics. The army reforms were not yet completed by the war of 1809, in which Charles acted as commander in chief, yet even so it proved a far more formidable opponent than the old and was only defeated after a desperate struggle involving Austrian victories and large loss of life on both sides.

Its initial successes were neutralised by the reverses of Abensberg, Landshut and Eckmühl but, after the evacuation of Vienna, the archduke won a strong victory at the Battle of Aspern-Essling but soon afterwards lost at the Battle of Wagram after heavy casualties on both sides. At the end of the campaign the archduke gave up all his military offices.

In 1808, when Napoleon had crowned his brother Joseph king of Spain, Archduke Charles had said to his brother, Emperor Francis II, "Now we know what Napoleon wants – he wants everything".

Later life

When Austria joined the ranks of the allies during the War of the Sixth Coalition, Charles was not given a command and the post of commander-in-chief of the allied Army of Bohemia went to the Prince of Schwarzenberg. Charles spent the rest of his life in retirement, except for a short time in 1815 when he was military governor of the Fortress Mainz. In 1822 he succeeded to the duchy of Saxe-Teschen.

On 15 September/17 September 1815 in Weilburg, Charles married Princess Henrietta of Nassau-Weilburg (1797–1829). She was a daughter of Frederick William of Nassau-Weilburg (1768–1816) and his wife Burgravine Louise Isabelle of Kirchberg.

Charles died at Vienna on 30 April 1847. He is buried in tomb 122 in the New Vault of the Imperial Crypt in Vienna. An equestrian statue was erected to his memory on the Heldenplatz in Vienna in 1860.

Assessment of his achievements
The caution which the archduke preached so earnestly in his strategic works, he displayed in practice only when the situation seemed to demand it, although his education certainly prejudiced him in favor of the defensive at all costs. He was at the same time capable of forming and executing the most daring offensive strategy, and his tactical skill in the handling of troops, whether in wide turning movements, as at Würzburg and Zürich, or in masses, as at Aspern and Wagram, was certainly equal to that of most leaders of his time, with only a few exceptions. Arthur Wellesley named Charles as the greatest general of his time. Charles was arguably the best commander ever produced by the House of Habsburg, and undoubtedly the most able Habsburg general of the French Revolutionary and Napoleonic era. Archduke Charles is credited with handing Napoleon his first major defeat. He has been described as the best general Republican France ever fought, with the exception of Alexander Suvorov.

According to the Encyclopædia Britannica Eleventh Edition, his campaign of 1796 is considered almost faultless. That he sustained defeat in 1809 was due in part to the great numerical superiority of the French and their allies, and in part to the condition of his newly reorganized troops. His six weeks' inaction after the victory of Aspern is, however, open to unfavorable criticism. As a military writer, his position in the evolution of the art of war is very important, and his doctrines had naturally the greatest weight. Nevertheless, they cannot but be considered antiquated even in 1806. Caution and the importance of strategic points are the chief features of his system. The rigidity of his geographical strategy may be gathered from the prescription that "this principle is never to be departed from."

Again and again he repeated the advice that nothing should be hazarded unless one's army is completely secure, a rule which he himself neglected with such brilliant results in 1796. Strategic points, he says, not the defeat of the enemy's army, decide the fate of one's own country, and must constantly remain the general's main concern, a maxim which was never more remarkably disproved than in the war of 1809. The editor of the archduke's work is able to make but a feeble defense against Clausewitz's reproach that Charles attached more value to ground than to the annihilation of the foe. In his tactical writings the same spirit is conspicuous. His reserve in battle is designed to "cover a retreat."

The baneful influence of these antiquated principles was clearly shown in the maintenance of Königgrätz-Josefstadt in 1866 as a strategic point, which was preferred to the defeat of the separated Prussian armies, and in the strange plans produced in Vienna for the campaign of 1859, and in the almost unintelligible Battle of Montebello in the same year. The theory and the practice of Archduke Charles form one of the most curious contrasts in military history. In the one he is unreal, in the other he displayed, along with the greatest skill, a vivid activity which made him for long the most formidable opponent of Napoleon.

He was the 831st Knight of the Order of the Golden Fleece in Austria.

Creation of the Austrian staff
When Karl Mack von Leiberich became chief of staff of the army under Prince Josias of Saxe-Coburg-Saalfeld in the Netherlands, he issued the Instruktionspunkte fur die gesamte Herren Generals, the last of 19 points setting out the roles of staff officers, dealing with offensive and defensive operations, while helping the Commander-in-chief. In 1796, Archduke Charles augmented these with his own Observationspunkte, writing of the Chief of Staff: "he is duty bound to consider all possibilities related to operations and not view himself as merely carrying out those instructions". On 20 March 1801, Feldmarschalleutnant Duka became the world's first peacetime Generalquartiermeister at the head of the staff and the wartime role of the Chief of Staff was now focused on planning and operations to assist the Commander. Archduke Charles produced a new Dienstvorschrift on 1 September 1805, which divided the staff into three: 1) Political Correspondence; 2) the Operations Directorate, dealing with planning and intelligence; 3) the Service Directorate, dealing with administration, supply and military justice. The Archduke set out the position of a modern Chief of Staff: "The Chief of Staff stands at the side of the Commander-in-Chief and is completely at his disposal. His sphere of work connects him with no specific unit". "The Commander-in-Chief decides what should happen and how; his chief assistant works out these decisions, so that each subordinate understands his allotted task". With the creation of the Korps in 1809, each had a staff, whose chief was responsible for directing operations and executing the overall headquarters plan.

Honours
• Austrian Empire:

• * Knight of the Golden Fleece, 1790

• * Grand Cross of the Military Order of Maria Theresa, in Diamonds, 1793

•  Kingdom of Bavaria: Knight of St. Hubert, 1844

•  Empire of Brazil: Grand Cross of the Southern Cross

•  Kingdom of France: Grand Cross of the Legion of Honour

•  Kingdom of Prussia:

• * Knight of the Black Eagle, 4 October 1835

• * Knight of the Red Eagle, 1st Class

•  Russian Empire:

• * Knight of St. Andrew

• * Knight of St. Alexander Nevsky

• * Knight of the White Eagle

• * Knight of St. Anna, 1st Class

•  Grand Duchy of Tuscany: Grand Cross of St. Joseph

•  Two Sicilies:

• * Knight of St. Januarius

• * Grand Cross of St. Ferdinand and Merit

•  undefined: Honorary Grand Cross of the Bath (military), 23 May 1834

Works

 * Grundsätze der Kriegskunst für die Generale (1806)
 * Grundsätze der Strategie erläutert durch die Darstellung des Feldzugs 1796 (1814)
 * Geschichte des Feldzugs von 1799 in Deutschland und in der Schweiz (1819)

title: Archduke Charles, Duke of Teschen